Antisense design
AssigneeRoche Innovation Center Copenhagen A/S
InventorsSigne M. Christensen, Nikolaj Dam Mikkelsen, Miriam Frieden, Henrik Frydenlund Hansen, Troels Koch, Daniel Sejer Pedersen, Christoph Rosenbohm, Charlotte Albaek Thrue, Majken Westergaard
Life of this patent
Estimating the term…
Abstract
A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
Claims78
A gapmer oligomer having 10-15 nucleotide units wherein a segment of 8-10 DNA nucleotides is flanked by locked nucleotides, and wherein at least one or all of the internucleotide linkages is a phosphorothioate linkage.
Dependencies are inferred from the claim text.